1,110 Shares in Stryker Co. (NYSE:SYK) Acquired by Morse Asset Management Inc

Morse Asset Management Inc bought a new position in shares of Stryker Co. (NYSE:SYK) during the first quarter, Holdings Channel.com reports. The fund bought 1,110 shares of the medical technology company’s stock, valued at approximately $397,000.

A number of other institutional investors have also made changes to their positions in SYK. Burkett Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the last quarter. Rogco LP acquired a new position in shares of Stryker during the 4th quarter worth approximately $30,000. DSM Capital Partners LLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $34,000. Finally, HBC Financial Services PLLC acquired a new position in shares of Stryker during the 4th quarter worth approximately $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK stock traded up $4.23 on Friday, hitting $331.67. 1,679,993 shares of the company’s stock were exchanged, compared to its average volume of 1,084,425. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The stock has a market cap of $126.35 billion, a P/E ratio of 37.86, a price-to-earnings-growth ratio of 2.61 and a beta of 0.89. The company has a 50 day moving average of $338.99 and a 200 day moving average of $339.32.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $2.14 earnings per share. On average, equities research analysts predict that Stryker Co. will post 11.95 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Friday, June 28th will be given a $0.80 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 annualized dividend and a yield of 0.96%. Stryker’s dividend payout ratio is presently 36.53%.

Analyst Ratings Changes

A number of research analysts have commented on SYK shares. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. The Goldman Sachs Group started coverage on Stryker in a report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 price objective on the stock. Royal Bank of Canada upped their price objective on Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Wells Fargo & Company upped their price objective on Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, UBS Group upped their price objective on Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $372.05.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.